-
Mashup Score: 122nd Biennial Miami Precision Medicine Conference | Sylvester Comprehensive Cancer Center - 3 day(s) ago
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies, and networking opportunities to shape the future of personalized healthcare.
Source: umiamihealth.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 122nd Biennial Miami Precision Medicine Conference | Sylvester Comprehensive Cancer Center - 3 day(s) ago
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies, and networking opportunities to shape the future of personalized healthcare.
Source: umiamihealth.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Treatment of Richter Transformation of Chronic Lymphocytic Leukemia in the Modern Era - 5 day(s) ago
Richter Transformation (RT) refers to the development of an aggressive lymphoma in the setting of chronic lymphocytic leukemia (CLL). While many variants of RT are recognized, diffuse large B-cell lymphoma (RT-DLBCL) is the most common (80%), followed by Hodgkin’s lymphoma (RT-HL, 19%). Diagnosis is based upon histologic evaluation of clinically suspicious lymph nodes. Positron emission tomography (PET) may be used to select the node of interest for biopsy. Although clonality testing is not a prerequisite of RT diagnosis, it has significant implications for survival. Clonally related DLBCL carries the worst prognosis with a median overall survival (OS) of less than one year in the era of combination chemotherapies with or without anti-CD20 antibodies. Prognosis has improved with the use of stem cell transplant and newer agents such as targeted therapy and newer forms of immunotherapy. Consideration of a clinical trial is encouraged. This review describes our current understanding of RT
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23Physician Advocacy is Key to Advancing Medicine - 7 day(s) ago
Sylvester physician-researcher Dr. Estelamari Rodriguez is re-elected to the Dade County Medical Association.
Source: www.linkedin.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 122nd Biennial Miami Precision Medicine Conference | Sylvester Comprehensive Cancer Center - 8 day(s) ago
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies, and networking opportunities to shape the future of personalized healthcare.
Source: umiamihealth.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13The Genomic, Transcriptomic, and Immunologic Landscape of HRAS Mutations in Solid Tumors - 13 day(s) ago
Tipifarnib is the only targeted therapy breakthrough for HRAS-mutant (HRASmt) recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The molecular profiles of HRASmt cancers are difficult to explore given the low frequency of HRASmt. This study aims to understand the molecular co-alterations, immune profiles, and clinical outcomes of 524 HRASmt solid tumors including urothelial carcinoma (UC), breast cancer (BC), non-small-cell lung cancer (NSCLC), melanoma, and HNSCC. HRASmt was most common in UC (3.0%), followed by HNSCC (2.82%), melanoma (1.05%), BC (0.45%), and NSCLC (0.44%). HRASmt was absent in Her2+ BC regardless of hormone receptor status. HRASmt was more frequently associated with squamous compared to non-squamous NSCLC (60% vs. 40% in HRASwt, p = 0.002). The tumor microenvironment (TME) of HRASmt demonstrated increased M1 macrophages in triple-negative BC (TNBC), HNSCC, squamous NSCLC, and UC; increased M2 macrophages in TNBC; and increased CD8+ T-cells in HNS
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 122nd Biennial Miami Precision Medicine Conference | Sylvester Comprehensive Cancer Center - 14 day(s) ago
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies, and networking opportunities to shape the future of personalized healthcare.
Source: umiamihealth.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 122nd Biennial Miami Precision Medicine Conference | Sylvester Comprehensive Cancer Center - 16 day(s) ago
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies, and networking opportunities to shape the future of personalized healthcare.
Source: umiamihealth.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41
Abstract. Non-small cell lung cancer (NSCLC) is associated with a 5-year survival rate of only 28%, however, when caught at an early stage, it can be cured with surgery or stereotactic body radiotherapy (SBRT). Unfortunately, racial disparities may result in limited access to care for some patients. Liu et al. analyzed 64,999 cases of early-stage NSCLC treated between 2005 and 2017 from the Florida cancer registry and showed that Black patients had 36% lower odds of receiving curative-intent surgery compared to their White counterparts. This study highlights significant racial disparities in treatment patterns that must be addressed urgently.
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 122nd Biennial Miami Precision Medicine Conference | Sylvester Comprehensive Cancer Center - 20 day(s) ago
Stay ahead in precision medicine with the 2nd Biennial Miami Precision Medicine conference. Join healthcare professionals for cutting-edge CME events, featuring expert insights, innovative strategies, and networking opportunities to shape the future of personalized healthcare.
Source: umiamihealth.orgCategories: General Medicine News, Hem/OncsTweet
The @sylvestercancer Miami Precision Medicine 2024 & Patient Symposium is back May 4-5, 2024! Live and Virtual event for International attendees! 👉 Learn more and REGISTER today: https://t.co/mwC2Jzf9rq. #PrecisionOncology #MPM2024 #PatientEducation @carmencalfa @GlopesMD https://t.co/vh8qGgURba